% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • akanz2 akanz2 Oct 11, 2012 9:32 AM Flag

    Anatomy of a Biotech Sale....

    Hope you don't mind if I reply....since I think they will be going alone initially and I think the market is digesting this probability.
    I don't expect Amarin to be a stand alone company 2 -3 yrs from now . I expect Joe Z and Paul Huff to roughly follow the time line of Reliants Omacor / Lovaza launch and eventual sale/ merger.

    If they can successfully launch , as I believe they will , and rapidly expand market share ,as I believe they will ....Amarin will sell for a lot higher then what many of you would accept ,if they sold by year end.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If Amarin does a go it alone launch, as I currently suspect, they need to be perfect in their execution so as to maximize the market perception of large initial penetration or once again the shares will be slammed by disappointment. Joe Z and Paul Huff have the experience but they currently lack the organization and infrastructure. I am not sure why they are being so coy with the self imposed "Quiet Period" when they need to move out smartly with their staff build out vice maintain share price by mysterious silence. Virtually all the postulated share value estimates both published by financial analysts and the wishful thinkers on this board are
      long term values based on Vascepa peak sales potential. They are not based on a company with unknown marketing potential, no sales experience and a share price many multilples lower than the optimistic predictions. Realisticly Take overs do not take place at Hundreds of percent in excess of current price, especially where there are lots of big holders with
      very low share price basis.

    • Akanz...

      Think we pretty much see eye to eye on this...There is no way that AMRN or its potential buyers can know what the value of Vascepa is until it goes to market and they find out what the medical community thinks of it. So both parties would be in the position of gambling in a situation where the consequences of being wrong could be in the multi billions. So it makes a lot more sense to test the market before selling.

      IMO..AMRN is perfectly capable and has enough money to bring this drug to market by themselves or with the help of an outside agency..Post suggesting this is a ruinous course are way off base here..

      ": ) JL

      Sentiment: Strong Buy

    • Stand alone company with ONE (unprofitable) product competing AGAINST big pharma AND big genereics??

    • digest this! errrrrrrrr........FART! U SUCK!

      Sentiment: Strong Sell

2.80+0.01(+0.36%)Aug 31 4:00 PMEDT